Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$3.69B |
| 2 |
Abbott
ABT
|
+$3.65B |
| 3 |
Qualcomm
QCOM
|
+$3.54B |
| 4 |
Procter & Gamble
PG
|
+$3.42B |
| 5 |
Accenture
ACN
|
+$3.28B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$2.86B |
| 2 |
AbbVie
ABBV
|
+$2.71B |
| 3 |
Valero Energy
VLO
|
+$1.86B |
| 4 |
Lockheed Martin
LMT
|
+$916M |
| 5 |
Halliburton
HAL
|
+$856M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 10.68% |
| 3 | Healthcare | 10.19% |
| 4 | Industrials | 8.63% |
| 5 | Consumer Discretionary | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3401
Vivid Seats
SEAT
$77M
| $78.6K | ﹤0.01% |
+13,306
| New | +$86.8K |
|
3402
Sagimet Biosciences
SGMT
$437M
| $78.4K | ﹤0.01% |
15,000
| – | – |
|
3403
Star Holdings Shares of Beneficial Interest
STHO
$112M
| $77K | ﹤0.01% |
+10,176
| New | +$83.8K |
|
3404
Owlet
OWLT
$153M
| $76.8K | ﹤0.01% |
14,935
| – | – |
|
|
SBC
3405
SBC Medical Group
SBC
$314M
| $76.1K | ﹤0.01% |
18,201
-9,140
| -33% | -$38.1K |
|
3406
Karyopharm Therapeutics
KPTI
$168M
| $74.8K | ﹤0.01% |
+13,429
| New | +$102K |
|
3407
Arena Group
AREN
$39M
| $69.1K | ﹤0.01% |
31,851
-13,362
| -30% | -$44.5K |
|
|
DFDV
3408
DeFi Development Corp
DFDV
$81.3M
| $68.8K | ﹤0.01% |
+20,914
| New | +$101K |
|
|
CLPR
3409
Clipper Realty
CLPR
$46.5M
| $67.7K | ﹤0.01% |
22,401
-17,136
| -43% | -$57.9K |
|
3410
Siebert Financial
SIEB
$68M
| $67.6K | ﹤0.01% |
35,189
| – | – |
|
3411
Spero Therapeutics
SPRO
$68.9M
| $66.8K | ﹤0.01% |
28,565
| – | – |
|
3412
Cognition Therapeutics
CGTX
$82.3M
| $64.5K | ﹤0.01% |
84,940
| – | – |
|
3413
Genelux
GNLX
$130M
| $60.5K | ﹤0.01% |
25,000
| – | – |
|
|
TEAD
3414
Teads Holding Co
TEAD
$75.2M
| $59.5K | ﹤0.01% |
90,279
-103
| -0.1% | -$73 |
|
3415
Biote Corp
BTMD
$69.2M
| $57K | ﹤0.01% |
42,188
-30,638
| -42% | -$61.6K |
|
3416
INmune Bio
INMB
$43.1M
| $56.8K | ﹤0.01% |
50,252
| – | – |
|
3417
Ispire Technology
ISPR
$89M
| $56.3K | ﹤0.01% |
30,614
-16,120
| -34% | -$41.6K |
|
3418
Myomo
MYO
$37.5M
| $55.1K | ﹤0.01% |
81,566
| – | – |
|
|
AGEN
3419
Agenus
AGEN
$249M
| $50.1K | ﹤0.01% |
15,000
-61
| -0.4% | -$202 |
|
3420
DHI Group
DHX
$166M
| $49.5K | ﹤0.01% |
17,605
| – | – |
|
3421
PepGen
PEPG
$133M
| $47.8K | ﹤0.01% |
+27,012
| New | +$152K |
|
3422
Skillsoft
SKIL
$56.9M
| $47.7K | ﹤0.01% |
11,123
| – | – |
|
3423
Alpha Teknova
TKNO
$266M
| $45.5K | ﹤0.01% |
15,747
-18,551
| -54% | -$52.2K |
|
|
SLSN
3424
Solesence Inc
SLSN
$66.4M
| $45K | ﹤0.01% |
47,387
| – | – |
|
|
FLNA
3425
Filana Therapeutics
FLNA
$43M
| $43.2K | ﹤0.01% |
25,561
-437
| -2% | -$900 |
|
Similar funds
Charles Schwab's Q1 2026 Portfolio in Review
As of Q1 2026, Charles Schwab held 3,535 positions worth $654B, up 1.7% from $644B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab deployed $21.4B of net new capital in Q1 2026, opening 79 new positions and adding to 1,903 existing holdings. Its largest new stake was JPMorgan Income ETF: 8,679,689 shares worth $400M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Cisco, an estimated $2.86B trimmed.
- Charles Schwab's largest Q1 2026 buy was JPMorgan Income ETF: 8,679,689 shares worth $400M.
- Charles Schwab added most to UnitedHealth in Q1 2026, an estimated $3.69B increase.
- Charles Schwab's biggest Q1 2026 reduction was Cisco, cutting an estimated $2.86B.
- Charles Schwab fully exited Comerica in Q1 2026, selling an estimated $412M.
- Charles Schwab's ten largest holdings make up 22% of its $654B portfolio in Q1 2026.
- Charles Schwab opened 79 new positions and closed 80 in Q1 2026.
- Charles Schwab's portfolio value rose 1.7% quarter-over-quarter to $654B.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.